Profound Research Helps Lead New gMG Trial—Results Point to Flexible, Effective Dosing
Profound Research is proud to share the publication of new clinical findings in the Annals of Clinical and Translational Neurology stemming from a landmark nationwide trial led in part by our Chief Scientific Officer, Dr. Gregory Sahagian. The study, conducted in partnership with Argenx and The Neurology Center of Southern California, evaluated the safety, tolerability, and efficacy of efgartigimod in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG).
The phase 3b open-label ADAPT NXT study explored two dosing regimens—fixed cycles and every-other-week (Q2W)—of efgartigimod, a neonatal Fc receptor blocker approved for the treatment of gMG. Sixty-nine adult participants were randomized to receive either dosing approach over a 21-week period.
Both groups showed substantial clinical improvement in their Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, with reductions in symptoms observed as early as Week 1 and sustained through the duration of the study. Notably, nearly half of the patients in both arms achieved *minimal symptom expression* (MG-ADL scores of 0–1), offering new hope for individuals living with this chronic neuromuscular disorder.
“These findings are an important step forward in our understanding of how to optimize long-term management of generalized myasthenia gravis,” said Dr. Gregory Sahagian. “Being part of this research not only highlights Profound’s commitment to advancing care through community-based trials, but also demonstrates the meaningful clinical benefit that tailored dosing strategies can bring to patients. We’re excited to continue working at the forefront of innovation in neurology research.”
Efgartigimod was well tolerated across both arms of the trial. The most common adverse events were mild to moderate and included COVID-19 infections, headache, and upper respiratory tract infections. The consistency of response and favorable safety profile reinforce efgartigimod’s role as an effective therapy for gMG and provide clinicians with flexible treatment options for sustained disease control.
This milestone underscores Profound Research’s growing impact in neurology and rare disease research. It also affirms our dedication to supporting sponsors and investigators in bringing advanced therapeutic options to patients where they are—through trusted local healthcare providers embedded in their communities.
The full study, “Efgartigimod for Generalized Myasthenia Gravis: Phase 3b ADAPT NXT Study,” can be accessed online here: [https://doi.org/10.1002/acn3.70051]
About Profound Research
Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, Indiana, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients.